The Health minister visited Oslo Cancer Cluster Incubator to gain insight into cancer research. As part of the visit he was asked to kill live human melanoma cells with two cancer products in the lab. One of them was Lytix Biopharma's drug candidate LTX-315.
Researcher Siri Tveito from the Institute of Cancer Research was his instructor. Lytix Biopharma collaborate closely with the research group she represents at Institute of Cancer Research.
Unni Hjelmaas, CEO, and Øystein Rekdal, CSO, represented Lytix Biopharma.